Research articles

ScienceAsia 48 (2022): 1047-1052 |doi: 10.2307/ scienceasia1047-1052.2022.SA2191

The study of the effect of dry extract of tribulus terrestris on antibody genesis and immune organs in experimental hemolytic anemia

Farida Ashurovaa*, Nodir Ruzimurodova, Liliya Sabirzyanovaa, Makhzuna Mukhsinovaa

 
ABSTRACT:     The study shows that in the process of developing hemolytic anemia (with the help of phenylhydrazine hydrochloride), a secondary immunodeficiency state is formed in mice. The number of antibody-forming cells in the spleen of mice with anemia is 1212.5±27.3, which is 3.60 times less than in the control. In anemic mice treated with a dry extract of Tribulus Terrestris, the immune response to EB was significantly increased by 2.60 times. The number of antibody- forming cells is 2.97 times higher than that of the immunodeficient group. The number of nucleated cells in the spleen compared with the control is a significant (1.42 times) increase in the total number of cells in the spleen. The titer of antibodies to sheep erythrocytes in the blood significantly increases by 1.46 times compared to the control group. The number of cells in the thymus significantly increased by 1.32 times, respectively. The number of cells in the lymph nodes increases by 1.41 times. The number of erythrocytes in peripheral blood increases by 1.18 times and leukocytes by 1.42 times. In terms of its stimulating activity, the dry extract of Tribulus Terrestris significantly outperforms that of Tribestan. The whole complex of studies shows that the dry extract of Tribulus Terrestris has the ability to increase immunological reactivity and stimulate the hematopoietic system in mice with hemolytic anemia.

Download PDF

55 Downloads 98 Views

a Senior researcher, MD, PhD, Institute of Immunology and human genomics of Academy of Science of the Republic of Uzbekistan, Tashkent, Uzbekistan
b Associate Professor of the Department, PhD, Tashkent State Dental Institute, Tashkent, Uzbekistan

* Corresponding author, E-mail:

Received 8 Aug 2022, Accepted 1 Nov 2022